| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S6333 R26051 |
Veiby (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
11.73 [0.23;597.58] C excluded (control group) |
0/51 0/593 | 0 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6335 R26064 |
Veiby (Oxcarbazepine) (Controls unexposed, sick), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: No | 10.66 [0.54;209.15] C | 0/51 3/3,773 | 3 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6170 R21988 |
Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 | Spina bifida | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 34.33 [0.49;2389.88] C | 0/2 0/52 | 0 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6096 R15866 |
Artama (Oxcarbazepine), 2005 | Spina bifida | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 9.53 [0.19;482.86] C | 0/99 0/939 | 0 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 13.65 [1.72;108.21] | 3 | 152 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed, sick) ; 3: Oxcarbazepine;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6333